Keythera (Suzhou) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Keythera") announced on February 18, 2022, that it has executed a clinical supply agreement with F. Hoffmann-La Roche Ltd (hereinafter referred to as "Roche") to conduct a clinical study to develop a combination therapy of KF-0210 and atezolizumab together for advanced solid tumors. This study was approved by China's National Medical Products Administration (NMPA).

KF-0210, an EP4 receptor antagonist, is a class 1 anti-tumor small molecule drug independently discovered by Keythera. It can increase the patient‘s anti-tumor immune function by regulating the tumor microenvironment, therefor reduce the tumor growth and metastasis. Preclinical studies have shown that the combination therapy of KF-0210 and immune checkpoint drug anti-PD-L1/PD-1 antibody/ies (has synergistic anti-tumor effect. The clinical trial of KF-0210 monotherapy was conducted in Australia and China and showed good safety and pharmacokinetic profiles.

There are unmet clinical needs for the patients with advanced solid tumors. Innovative drugs are urgently needed. Recently, the research evidence has indicated that the combination of small molecule drugs with biological immune therapy can significantly improve their anti-tumor efficacy. The upcoming clinical study of KF-0210 in combination with atezolizumab, an anti-PD-L1/PD-1 antibody (antibody, will advance the clinical development of such a therapy in China. Hopefully, this clinical study will be successful and can benefit the cancer patients soon.

Keythera is a biotech company, founded by a team of senior scientists with global drug discovery and development experience. Keythera focuses on the development of innovative therapies for tumors and autoimmune diseases to meet the unmet medical needs. Keythera has established comprehensive development strategies and product pipelines, with its goal to provide the most cutting-edge new therapies to patients.

Back to List